We tested the hypothesis that nitric oxide (NO) exerts a tonic inhibitory influence on cytochrome P450 (CYP450)-dependent metabolism of arachidonic acid (AA). 2. N(omega)-nitro-L-Arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS), increased mean blood pressure (MBP), from 91+/-6 to 137+/-5 mmHg, renal vascular resistance (RVR), from 9.9+/-0.6 to 27.4+/-2.5 mmHg ml(-1) min(-1), and reduced renal blood flow (RBF), from 9.8+/-0.7 to 6.5+/-0.6 ml min(-1)) and GFR from 1.2+/-0.2 to 0.6+/-0.2 ml 100 g(-1) min(-1)) accompanied by diuresis (UV, 1.7+/-0.3 to 4.3+/-0.8 microl 100 g(-1) min (-1)), and natriuresis (U(Na)V, 0.36+/-0.04 to 1.25+/-0.032 micromol 100 g(-1) min(-1)). 3. 12, 12 dibromododec-enoic acid (DBDD), an inhibitor of omega hydroxylase, blunted L-NAME-induced changes in MBP, RVR, UV and U(Na)V by 63+/-8, 70+/-5, 45+/-8 and 42+/-9%, respectively, and fully reversed the reduction in GFR by L-NAME. Clotrimazole, an inhibitor of the epoxygenase pathway of CYP450-dependent AA metabolism, was without effect. 4. BMS182874 (5-dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfo namide), an endothelin (ET)A receptor antagonist, also blunted the increases in MBP and RVR and the diuresis/natriuresis elicited by L-NAME without affecting GFR. 5. Indomethacin blunted L-NAME-induced increases in RVR, UV and U(Na)V. BMS180291 (1S-(1alpha,2alpha,3alpha,4alpha)]-2-[[3-[4-[(++ +pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl ]methyl]benzenepropanoic acid), an endoperoxide receptor antagonist, attenuated the pressor and renal haemodynamic but not the renal tubular effects of L-NAME. 6. In conclusion, the renal functional effects of the CYP450-derived mediator(s) expressed after inhibition of NOS with L-NAME were prevented by inhibiting either CYP450 omega hydroxylase or cyclooxygenase or by antagonizing either ET(A) or endoperoxide receptors. 20-hydroxyeicosatetraenoic acid (20-HETE) fulfils the salient properties of this mediator.
摘要
我们检验了一氧化氮(NO)对细胞色素P450(CYP450)依赖的花生四烯酸(AA)代谢产生持续性抑制作用这一假说。2. 一氧化氮合酶(NOS)抑制剂N(ω)-硝基-L-精氨酸甲酯(L-NAME)使平均血压(MBP)从91±6 mmHg升高至137±5 mmHg,肾血管阻力(RVR)从9.9±0.6 mmHg ml⁻¹ min⁻¹升高至27.4±2.5 mmHg ml⁻¹ min⁻¹,并使肾血流量(RBF)从9.8±0.7 ml min⁻¹降至6.5±0.6 ml min⁻¹,肾小球滤过率(GFR)从1.2±0.2 ml 100 g⁻¹ min⁻¹降至0.6±0.2 ml 100 g⁻¹ min⁻¹,同时伴有利尿(尿流量,UV,从1.7±0.3升至4.3±0.8 μl 100 g⁻¹ min⁻¹)和排钠(尿钠排泄量,U(Na)V,从0.36±0.04升至1.25±0.032 μmol 100 g⁻¹ min⁻¹)。3. ω羟化酶抑制剂12,12-二溴十二碳烯酸(DBDD)使L-NAME诱导的MBP、RVR、UV和U(Na)V变化分别减弱63±8%、70±5%、45±8%和42±9%,并完全逆转L-NAME所致的GFR降低。克霉唑是CYP450依赖的AA代谢环氧合酶途径的抑制剂,无此作用。4. 内皮素(ET)A受体拮抗剂BMS182874(5-二甲基氨基)-N-(3,4-二甲基-5-异恶唑基)-1-萘磺酰胺)也减弱L-NAME引起的MBP和RVR升高以及利尿/排钠作用,但不影响GFR。5. 吲哚美辛减弱L-NAME引起的RVR、UV和U(Na)V升高。内过氧化物受体拮抗剂BMS180291(1S-(1α,2α,3α,4α)]-2-[[3-[4-[(戊基氨基)羰基]-2-恶唑基]-7-氧杂双环[2.2.1]庚-2-基]甲基]苯丙酸)减弱L-NAME的升压和肾血流动力学作用,但不减弱其肾小管作用。6. 总之,用L-NAME抑制NOS后表达的CYP450衍生介质的肾功能效应,可通过抑制CYP450 ω羟化酶或环氧化酶,或拮抗ET(A)或内过氧化物受体来预防。20-羟基二十碳四烯酸(20-HETE)符合该介质的主要特性。